G R Graff

Summary

Affiliation: University of Missouri
Country: USA

Publications

  1. ncbi Chronic lung disease after activated charcoal aspiration
    Gavin R Graff
    University of Missouri Hospital and Clinics, Columbia, MO 65212, USA
    Pediatrics 109:959-61. 2002
  2. ncbi Use of a remifentanil-propofol mixture for pediatric flexible fiberoptic bronchoscopy sedation
    John W Berkenbosch
    Department of Child Health, The University of Missouri Columbia, Columbia, MO 65212, USA
    Paediatr Anaesth 14:941-6. 2004
  3. ncbi Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid
    G R Graff
    Department of Child Health, University of Missouri Columbia, 65212, USA
    Respiration 68:91-4. 2001
  4. ncbi Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis
    Gavin R Graff
    Department of Child Health, University of Missouri Columbia, Columbia, MO 65212, USA
    Chest 121:1754-60. 2002
  5. ncbi Safety and efficacy of ketamine sedation for infant flexible fiberoptic bronchoscopy
    John W Berkenbosch
    Department of Child Health, The University of Missouri Columbia, 65212, USA
    Chest 125:1132-7. 2004
  6. ncbi Montelukast pharmacokinetics in cystic fibrosis
    Gavin R Graff
    University of Missouri, Department of Child Health and Molecular Microbiology, Columbia, Missouri, USA
    J Pediatr 142:53-6. 2003
  7. ncbi Patterns of helium-oxygen (heliox) usage in the critical care environment
    John W Berkenbosch
    Department of Child Health, University of Missouri Columbia, USA
    J Intensive Care Med 19:335-44. 2004
  8. ncbi Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient
    Gavin R Graff
    Department of Pediatrics, Penn State College of Medicine, Penn State Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    Respiration 71:646-9. 2004
  9. ncbi Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health
    Hephzibah Rani S Tagaram
    Departments of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    Am J Physiol Lung Cell Mol Physiol 292:L1052-63. 2007

Collaborators

Detail Information

Publications9

  1. ncbi Chronic lung disease after activated charcoal aspiration
    Gavin R Graff
    University of Missouri Hospital and Clinics, Columbia, MO 65212, USA
    Pediatrics 109:959-61. 2002
    ..We report a case of inadvertent administration of activated charcoal into the trachea that resulted in the development of chronic lung disease...
  2. ncbi Use of a remifentanil-propofol mixture for pediatric flexible fiberoptic bronchoscopy sedation
    John W Berkenbosch
    Department of Child Health, The University of Missouri Columbia, Columbia, MO 65212, USA
    Paediatr Anaesth 14:941-6. 2004
    ..However, delivery of these agents as a combined, single infusion has not been described...
  3. ncbi Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid
    G R Graff
    Department of Child Health, University of Missouri Columbia, 65212, USA
    Respiration 68:91-4. 2001
    ..Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications...
  4. ncbi Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis
    Gavin R Graff
    Department of Child Health, University of Missouri Columbia, Columbia, MO 65212, USA
    Chest 121:1754-60. 2002
    ....
  5. ncbi Safety and efficacy of ketamine sedation for infant flexible fiberoptic bronchoscopy
    John W Berkenbosch
    Department of Child Health, The University of Missouri Columbia, 65212, USA
    Chest 125:1132-7. 2004
    ..To describe our experience with ketamine sedation during infant flexible fiberoptic bronchoscopy...
  6. ncbi Montelukast pharmacokinetics in cystic fibrosis
    Gavin R Graff
    University of Missouri, Department of Child Health and Molecular Microbiology, Columbia, Missouri, USA
    J Pediatr 142:53-6. 2003
    ..The effectiveness of these concentrations for the inflammatory lung disease of patients with CF is unknown...
  7. ncbi Patterns of helium-oxygen (heliox) usage in the critical care environment
    John W Berkenbosch
    Department of Child Health, University of Missouri Columbia, USA
    J Intensive Care Med 19:335-44. 2004
    ..As a benign and relatively inexpensive therapy, heliox use should continue to be attractive, although ongoing study regarding efficacy in a number of settings is indicated...
  8. ncbi Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient
    Gavin R Graff
    Department of Pediatrics, Penn State College of Medicine, Penn State Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    Respiration 71:646-9. 2004
    ....
  9. ncbi Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health
    Hephzibah Rani S Tagaram
    Departments of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    Am J Physiol Lung Cell Mol Physiol 292:L1052-63. 2007
    ..10) compared with culture-positive NCF (0.368 +/- 0.085). In summary, we developed and characterized an SP-A1 gene-specific antibody and used it to identify gene-specific SP-A content in BALFs as a function of age and lung health...